Ginkgo Bioworks Holdings, Inc. (DNA)
$
5.93
-0.48 (-8.09%)
Key metrics
Financial statements
Free cash flow per share
-3.4990
Market cap
367.2 Million
Price to sales ratio
2.1581
Debt to equity
0.8201
Current ratio
4.9165
Income quality
0.5469
Average inventory
0
ROE
-0.5372
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ginkgo Bioworks Holdings, Inc., along with its subsidiaries, specializes in developing a platform for cell programming that facilitates the biological production of various products such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a diverse range of end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. As a testament to its operational performance, the company recorded an operating income of -$315,278,000.00 reflecting its earnings from core operations. The gross profit ratio is 0.81 showcasing the efficiency of the company's production and sales operations, while the gross profit stands at $138,634,000.00 highlighting its profitability from core activities. The company's stock is identified with the symbol 'DNA' in the market, and the operating income ratio is -1.85 indicating the company's operational profitability margin. Additionally, Ginkgo Bioworks has established a partnership with Selecta Biosciences, Inc. to advance the ImmTOR technology platform. Founded in 2008, the company is headquartered in Boston, Massachusetts. In the market landscape, the stock is affordable at $11.37 catering to budget-conscious investors. With a high average trading volume of 1,091,449.00 the stock indicates strong liquidity, making it an appealing option for traders. Ginkgo Bioworks, classified as a small-cap player with a market capitalization of $367,211,384.00 is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth while playing a vital role in shaping future developments in its field.
Is Ginkgo Bioworks Holdings, Inc. (DNA) a good investment?
Investing in Ginkgo Bioworks Holdings, Inc. (DNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Ginkgo Bioworks Holdings, Inc. (DNA)'s stock forecast?
Analysts predict Ginkgo Bioworks Holdings, Inc. stock to fluctuate between $5 (low) and $17.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ginkgo Bioworks Holdings, Inc.'s market capitalization?
As of 2026-03-27, Ginkgo Bioworks Holdings, Inc.'s market cap is $367,211,384, based on 61,924,348 outstanding shares.
How does Ginkgo Bioworks Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ginkgo Bioworks Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ginkgo Bioworks Holdings, Inc. (DNA) stock?
To buy Ginkgo Bioworks Holdings, Inc. (DNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Ginkgo Bioworks Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ginkgo Bioworks Holdings, Inc. stock ever split?
Ginkgo Bioworks Holdings, Inc.'s last stock split was 1:40 on 2024-08-20.
How did Ginkgo Bioworks Holdings, Inc. perform in the last earnings report?
Revenue: $170,155,000 | EPS: -$5.64 | Growth: -46.49%.
Where can I find Ginkgo Bioworks Holdings, Inc.'s investor relations reports?
Visit https://www.ginkgobioworks.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ginkgo Bioworks Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Ginkgo Bioworks Holdings, Inc. stock?
All-time high: $634.56 (2021-11-09) | All-time low: $5 (2025-04-04).
What are the key trends affecting Ginkgo Bioworks Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
seekingalpha.com
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
prnewswire.com
Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
zacks.com
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9, representing a -3.12% change from its previous close.
seekingalpha.com
Amazon delivered robust Q4 2025 results, with accelerating revenue growth and AWS leading at 23.6% YoY. AMZN's operating margin reached a historic high of 11.8%, driven by strong AWS profitability at a 35% margin. The stock sold off after management guided FY 2026 CapEx to $200bn, 50% above FY 2025 and exceeding operating cash flow by $60bn.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.
seekingalpha.com
Allegiant Travel Company demonstrates disciplined capacity management and cost control, supporting a "Buy" rating and strong post-earnings stock performance. Q4 2025 results show a swing to profitability with a 10.2% operating margin, despite modest margin compression and reduced unit revenues. ALGT targets stable capacity and efficiency gains in 2026, leveraging Boeing 737 MAX upgrades to drive cost improvements without diluting unit revenues.
zacks.com
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $8.27, denoting a -5.92% move from the preceding trading day.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.31, signifying a -1.27% move from its prior day's close.
zacks.com
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.02, marking a -6.36% move from the previous day.
See all news
